Evidence map›Paper›PMID 29575242›Full record

ArticlePharmacoepidemiology and drug safety2018

Methodology for computing the burden of disease of adverse events following immunization.

Scott A McDonald, Danielle Nijsten, Kaatje Bollaerts, Jorgen Bauwens, Nicolas Praet, Marianne van der Sande, Vincent Bauchau, Tom de Smedt, Miriam Sturkenboom, Susan Hahné

Open access · hybridAbstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Scott A McDonaldNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID 0000-0003-0788-6011
Danielle NijstenNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Kaatje BollaertsP95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium.
Jorgen BauwensUniversity of Basel Children's Hospital, Basel, Switzerland.
Nicolas PraetGlaxoSmithKline Vaccines, Rixenart, Belgium.
Marianne van der SandeNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Vincent BauchauGlaxoSmithKline Vaccines, Rixenart, Belgium.
Tom de SmedtP95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium.
Miriam SturkenboomP95 Pharmacovigilance and Epidemiology Services, Leuven, Belgium.
Susan HahnéNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
National Institute for Public Health and the Environment · NLGlaxoSmithKline (Belgium) · BEKU Leuven · BESwiss Vaccine Research Institute · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeComposite disease burden measures such as disability-adjusted life-years (DALY) have been widely used to quantify the population-level health impact of disease or injury, but application has been limited for the estimation of the burden of adverse events following immunization. Our objective was to assess the feasibility of adapting the DALY approach for estimating adverse event burden.

methodsWe developed a practical methodological framework, explicitly describing all steps involved: acquisition of relative or absolute risks and background event incidence rates, selection of disability weights and durations, and computation of the years lived with disability (YLD) measure, with appropriate estimation of uncertainty. We present a worked example, in which YLD is computed for 3 recognized adverse reactions following 3 childhood vaccination types, based on background incidence rates and relative/absolute risks retrieved from the literature.

resultsYLD provided extra insight into the health impact of an adverse event over presentation of incidence rates only, as severity and duration are additionally incorporated. As well as providing guidance for the deployment of DALY methodology in the context of adverse events associated with vaccination, we also identified where data limitations potentially occur.

conclusionsBurden of disease methodology can be applied to estimate the health burden of adverse events following vaccination in a systematic way. As with all burden of disease studies, interpretation of the estimates must consider the quality and accuracy of the data sources contributing to the DALY computation.

Indexed as

Research DesignAdolescentChildChild, PreschoolCost of IllnessHumansImmunizationInfantQuality-Adjusted Life YearsRisk AssessmentUnited KingdomVaccinesVaccinesadverse eventsdisability-adjusted life-yearsdisease burdenmethodologypharmacoepidemiologyvaccination

Identifiers

PMID29575242
PMCPMC6055877
OpenAlexW2794018611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.